Compounded semaglutide vs Wegovy. The honest breakdown.

Quick comparison at a glance

The short version — here is how Compounded Semaglutide and Wegovy stack up on the questions most patients ask before picking one.

Compounded Semaglutide

• Drug class: GLP-1 receptor agonist, compounded
• Brand names: (custom compounded formulations)
• Mechanism: Same active ingredient as brand semaglutide — mimics the gut hormone GLP-1 to reduce appetite, slow gastric emptying, and modulate blood sugar.
• Dosing: Typically once-weekly subcutaneous injection. Dose ranges depend on the pharmacy's formulation and the prescriber's titration schedule.
• Half-life: Semaglutide's half-life is about 7 days regardless of source.
• FDA indication: None — compounded semaglutide is not an FDA-approved product with an indication. It is prescribed off-label at the physician's discretion, typically for weight management.
• FDA status: NOT FDA-approved. Compounded by state-licensed pharmacies under a valid prescription, in accordance with federal compounding law during declared shortages.
• Manufacturer: Licensed compounding pharmacies (not Novo Nordisk, not any brand manufacturer).
• Common side effects: Expected to be similar to brand semaglutide — nausea, vomiting, diarrhea, decreased appetite — but side effect and quality-control profiles have not been independently evaluated by the FDA.
• Typical price range: Typically $150-$400/month depending on the pharmacy and dose. Puri's compounded semaglutide program starts at $179/month when clinically appropriate.

Wegovy

• Drug class: GLP-1 receptor agonist, FDA-approved finished drug product
• Brand names: Wegovy (semaglutide 2.4 mg)
• Mechanism: Synthetic semaglutide that mimics the gut hormone GLP-1. FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition.
• Dosing: Once-weekly subcutaneous injection. Titrated from 0.25 mg to 2.4 mg over about 16 weeks, per the FDA-approved prescribing information.
• Half-life: Approximately 7 days.
• FDA indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Also indicated for cardiovascular risk reduction in certain patients.
• FDA status: FDA-approved as a finished drug product. Has undergone Phase 3 clinical trials (STEP 1-5) and continues to be monitored post-market.
• Manufacturer: Novo Nordisk
• Common side effects: Nausea, vomiting, diarrhea, constipation, decreased appetite. Well-characterized from clinical trials involving thousands of patients and ongoing post-market surveillance.
• Typical price range: Roughly $1,300+/month cash price without insurance. Some insurance plans cover it for the FDA-approved indication with prior authorization; many do not.

What compounding actually is (and isn't)

Pharmacy compounding is the custom preparation of a medication for an individual patient by a licensed pharmacist, in response to a valid prescription from a licensed prescriber. Compounding has existed for as long as pharmacy has — traditionally it was used to make a child's dose from an adult tablet, remove an allergen, or combine multiple medications into one.

Under federal law, compounding pharmacies fall into two categories. 503A pharmacies prepare compounded medications for specific patients based on individual prescriptions. 503B outsourcing facilities can compound in larger batches under stricter FDA oversight. Both operate under specific rules about which drugs can be compounded, when, and how.

When the FDA declares a shortage of a brand-name drug — as it did for semaglutide during the Wegovy and Ozempic shortages — compounding of that drug becomes legally permissible under specific conditions. Pharmacies can compound a product that is "essentially a copy" of the brand-name drug only during an active shortage, and only from legitimate bulk active pharmaceutical ingredient (API) sourced from FDA-registered facilities.

What FDA approval actually guarantees

Understanding what FDA approval means helps clarify what you do and don't get with a compounded alternative.

For brand-name Wegovy, FDA approval means the product has been through Phase 1, 2, and 3 clinical trials demonstrating that it is safe and effective for its FDA-approved indication. It means the manufacturing facility has been inspected, the active ingredient and inactive excipients have been characterized, the dosing has been validated across thousands of patients, and ongoing post-market safety monitoring is required by the FDA.

For compounded semaglutide, none of those are true. The FDA has not reviewed the compounded product, has not verified its purity or potency batch-to-batch, and has not evaluated it for equivalence to Wegovy. A responsible compounding pharmacy will source API from FDA-registered facilities, test for sterility and potency, and follow USP guidelines — but the regulatory floor is fundamentally different.

This is not an argument that compounded semaglutide is unsafe. It is an argument that you should understand what you are getting so you can make an informed decision with a licensed physician.

Why the specific pharmacy matters

Not all compounding pharmacies are equal. The 503A pharmacy category is regulated primarily at the state level, and quality control standards vary. Some pharmacies invest heavily in third-party testing, cleanroom facilities, and documentation. Others cut corners.

• API sourcing. A legitimate compounding pharmacy sources semaglutide API from FDA-registered manufacturing facilities, with certificates of analysis and chain-of-custody documentation. The FDA has issued warnings about compounded semaglutide made from illicit API sources, including products labeled as "salt forms" that are not the same active ingredient at all.
• Sterility testing. Injectable products must be prepared in sterile conditions and tested for sterility, endotoxins, and particulates. Any injection that is not prepared to these standards carries serious infection risk.
• Potency testing. Third-party potency testing confirms that the compounded product actually contains the dose labeled on the vial.
• Licensing and inspection history. State pharmacy boards inspect compounding pharmacies. Checking a pharmacy's licensing and disciplinary history is a reasonable due-diligence step before using their products.

Puri works exclusively with state-licensed 503A and 503B compounding pharmacies that meet our sourcing, sterility, and documentation requirements. We do not use pharmacies that source API from uncharacterized supply chains.

When each path actually makes sense

The honest framing on when to choose which path:

Wegovy is typically the right starting point if:

• Your insurance covers Wegovy for the FDA-approved indication, even with prior authorization.
• You can afford the cash price ($1,300+/month) and want the most clinical data behind your treatment.
• You specifically want an FDA-approved product and are willing to pay the premium for that regulatory backing.
• You are a patient for whom the FDA-approved dosing schedule (0.25-2.4 mg weekly titration) is the right clinical plan.

Compounded semaglutide may be reasonable if:

• Brand-name Wegovy is unavailable or back-ordered in your area.
• Your insurance does not cover Wegovy, and the cash price is financially out of reach.
• A licensed physician has reviewed your clinical picture and determined that semaglutide is appropriate.
• You are using a reputable compounding pharmacy with documented API sourcing and third-party quality control (which is what Puri requires).
• You understand and accept that compounded medications are not FDA-approved and have not been independently evaluated by the FDA.

Who tends to do better on each

There is no universally better option — only a better fit for your specific clinical picture, history, budget, and preferences. A licensed physician reviews all of those before prescribing. Here is the honest framing on who typically does better on each.

Compounded Semaglutide

Compounded semaglutide is often an accessible path for patients who cannot obtain brand-name Wegovy due to cost, insurance denials, or supply shortages. It is a legal option when prescribed by a licensed physician during an FDA-declared shortage of the brand product. Patients should understand that the product has not been independently evaluated by the FDA, and the decision to use compounded semaglutide should be made with a physician who can explain the trade-offs honestly.

Wegovy

Wegovy is the right choice for patients who want the most clinical evidence, predictable quality from an FDA-approved product, and insurance coverage (when available). It is the baseline against which any alternative should be evaluated. Patients with insurance that covers Wegovy or who can afford the cash price should generally start here.